Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript

Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High – Here’s Why

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High on Analyst Upgrade

Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade

Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement

Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.

Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $30,244.20 in Stock

Bicara Therapeutics Inc. (BCAX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Market Today: Oil shock, NVDA's $4B bet, BRK.B slides, gold jumps, AAPL unveils low-cost iPhone

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Bleakley Financial Group LLC Makes New $481,000 Investment in Bicara Therapeutics Inc. $BCAX

Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ivan Hyep Sells 1,882 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Ryan Cohlhepp Sells 3,828 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025

Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity